A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

"We found that preexisting depression was associated with a 2.5-fold increase in mortality risk for patients with PCa, highlighting its role in exacerbating disease progression and worsening survival.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Cancer death rates in the UK have hit a record low, but the picture is more complicated than the headline figure suggests.

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.